Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Gymnema Sylvestre vs Tirzepatide: Tirzepatide has the stronger overall evidence (7.8 vs 5.5/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Tirzepatide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (2)
Outcomes where both Gymnema Sylvestre and Tirzepatide have evidence — compare verdict strength side-by-side.
200-400mg standardized extract (≥25% gymnemic acids) 1-2x daily, or 2-4g dried leaf
With meals
Standardized extract (≥25% gymnemic acids)
Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)
Any time of day
Once-weekly subcutaneous injection (Mounjaro / Zepbound)
8-12 weeks
Immediate-2 weeks
8-12 weeks
Days
Weeks to months
Months (dose-escalated over ~20 weeks)
Weeks to months
Mostly during titration
The effect of Gymnema sylvestre supplementation on glycemic control in type 2 diabetes patients: A systematic review and meta-analysis.
Phytotherapy research : PTR (2021) · Meta analysis
Significant reductions in fasting blood glucose and HbA1c versus control
The effects of Gymnema Sylvestre supplementation on lipid profile, glycemic control, blood pressure, and anthropometric indices in adults: A systematic review and meta-analysis.
Phytotherapy research : PTR (2023) · Meta analysis
Reductions in fasting glucose and improvements in lipid profile
A systematic review of Gymnema sylvestre in obesity and diabetes management.
Journal of the science of food and agriculture (2014) · Systematic review
Possible benefits for glycemic control and body weight
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
N Engl J Med (2021) · Rct · n=1879
Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg
Tirzepatide Once Weekly for the Treatment of Obesity.
N Engl J Med (2022) · Rct · n=2539
72-week phase-3 double-blind RCT (SURMOUNT-1) in 2539 adults with obesity (without diabetes), tirzepatide 5/10/15 mg vs placebo
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
N Engl J Med (2025) · Rct · n=751
Phase-3b open-label head-to-head RCT (SURMOUNT-5) in 751 adults with obesity but without diabetes, max-tolerated tirzepatide vs max-tolerated semaglutide
Tirzepatide has a higher evidence score (7.8/10 vs 5.5/10) and wins in 2 of 3 categories.
For manage weight, Tirzepatide has a higher relevance score (90 vs 60).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.